OttavioValerioVitoloMD

Neuropsychiatry

Neuropsychiatrist, Massachusetts General Hospital

Dr. Vitolo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Vitolo is a board-certified psychiatrist and neuropsychiatrist with extensive experience in academia, clinical research, and the biotechnology industry. He serves as a neuropsychiatrist at Massachusetts General Hospital and as a Lecturer in Psychiatry at Harvard Medical School. His work has focused on neuropsychiatric disorders, neurodegenerative diseases, and drug development, with leadership roles in major biotech and pharmaceutical companies. His expertise spans translational medicine, clinical trial design, and biomarker research. Committed to advancing treatments for psychiatric and neurological disorders, Dr. Vitolo provides specialized care for individuals with neuropsychiatric and neurodegenerative conditions.

Harvard Medical SchoolM.M.Sc., Translational Medicine, 2010 - 2012
Brigham and Women's HospitalBehavioral Neurology and Neuropsychiatry, 2008 - 2009
Washington University/B-JH/SLCH ConsortiumResidency, Psychiatry, 2004 - 2008
Sapienza University of RomeClass of 1998

MA State Medical License 2008 - 2025
American Board of Psychiatry and Neurology Psychiatry
United Council for Neurologic SubspecialtiesBehavioral Neurology and Neuropsychiatry

PubMed

1 citations
"When Will All of This End?": A 65-Year-Old Man With Amyotrophic Lateral Sclerosis and Psychiatric Distress.
Ethan G Lester, Ottavio V Vitolo, Alice Flaherty, Yvan Beaussant, Margaret Cramer
The Journal of Clinical Psychiatry. 2023-12-13
1 citations
Resilient together-ALS: leveraging the NDD transdiagnostic framework to develop an early dyadic intervention for people with amyotrophic lateral sclerosis and their in...
Christina L Rush, Ethan G Lester, Heena Manglani, Emily Woodworth, Ottavio Vitolo
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2023-06-22
52 citations
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.
Maurizio Fava, Stephen Stahl, Luca Pani, Sara De Martin, Marco Pappagallo
The American Journal of Psychiatry. 2022-02-01

Relmada Therapeutics Stock Soars on Phase 2 Depression Study ResultsOctober 15th, 2019
Relmada Therapeutics Announces Publication of REL1017 Phase 1 Studies ResultsApril 16th, 2019